Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
CASI pharmaceuticals, Inc.
Hol
Kína6 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
75 fő, tervezett
Kezdés
2025. jan. 3.
Várható befejezés
2026. dec. 30.
A vizsgálat típusa
Beavatkozással járó, 8 csoport
A vizsgált kezelések
  • CID-103
A regiszteradat frissítve
2025. június 12.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with chronic immune thrombocytopenia (ITP, a low platelet count caused by the immune system) to test the safety and effect of CID-103 given by drip into a vein.

Életkor
18 to 65 years
Nem
Male and female
A betegség stádiuma
ITP lasting 3 months or longer, with a mean platelet count ≤ 35 x 10^9/L on at least two tests at least one week apart.
Korábbi kezelés
At least two earlier lines of standard treatment (corticosteroids and one other drug). An earlier ITP treatment (not a TPO-RA) must have raised platelets to ≥ 30 x 10^9/L and doubled the starting count. Any ongoing ITP treatment must be stable for at least four weeks.

A részvétel fő kizáró okai

  • Any earlier anti-CD38 drug, or BTK, FcRn or complement drugs within three months
  • Rituximab or spleen removal within three months; IV, subcutaneous or anti-D immunoglobulin within four weeks
  • Blood thinners or drugs like aspirin within three weeks
  • Blood clot within six months, serious heart disease, severe COPD or asthma, or active cancer
  • Pregnancy or breastfeeding, active hepatitis B or C, or HIV with CD4+ count < 350/μL

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female individuals aged 18 to 65 years at time of signing of ICF. Disease-related
  • Diagnosed with ITP that has persisted for ≥ 3 months, diagnosed in accordance with The American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia or the Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (as locally applicable)
  • Diagnosis of ITP supported by a prior response to an ITP treatment (other than a thrombopoietin receptor agonists [TPO-RA]) that achieved a platelet count of ≥ 30 x 10\^9/L and a doubling of baseline measurement
  • Has received at least two lines of SOC systemic treatment (i.e., corticosteroids and one other agent)
  • Has a mean platelet count ≤ 35 x 10\^9/L on at least two measurements at least one week apart during screening
  • If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least four weeks prior to first dose of CID-103
  • Adequate organ function
  • Contraception: Female participants must either be non-pregnant or not breastfeeding and must have a negative pregnancy test. Male and female participants must meet the contraceptive requirements

Ki nem vehet részt

  • Prior treatment with any anti-CD38 agent, or has been treated with anti-Bruton's tyrosine kinase (BTK), neonatal Fc receptor (FcRn) antagonist or complement inhibitor within three months prior to first dose of CID-103
  • Treatment with rituximab or splenectomy within the three months prior to first dose of CID-103
  • Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within three weeks before screening
  • Receiving other concurrent investigational therapies or have received investigational therapies within four weeks of the first dose of CID-103 or five half-lives (if shorter)
  • Has a history of any thrombotic or embolic event within six months before screening
  • Diagnosed with severe chronic obstructive pulmonary disease (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD Stage 3 or 4) or asthma
  • Has been diagnosed with myelodysplastic syndrome or other active malignancy
  • Clinically significant medical history or ongoing chronic illness
  • Known active infection with hepatitis B (HBV) (surface antigen) or infection with hepatitis C (HCV) in absence of sustained virologic response
  • History of known or suspected immunosuppression
  • A history or evidence of cardiovascular risk including left ventricular ejection fraction < 50%, clinically significant uncontrolled ventricular arrhythmia, acute coronary syndrome history, coronary angioplasty or stenting within six months, current ≥ Class III congestive heart failure (NYHA guidelines), and treatment refractory hypertension
  • Known active infection with human immunodeficiency virus (HIV) and CD4+ T cell count < 350/μL
  • Use of IV immunoglobulin, subcutaneous immunoglobulin or anti-D immunoglobulin treatment within four weeks of screening
  • Active hemolytic anemia
  • Known / clinically significant amyloidosis
  • Karnofsky Performance Status ≤ 70

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are:

A teljes eredeti leírásKevesebb

* To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103. * To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy.

The study will be done in two parts:

Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range.

Part B will compare up to three different doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.

CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 6 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness.

This study is an important step toward developing a new treatment for people living with chronic ITP. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.

A vizsgálat 8 csoportja

  • Part B (Randomized Dose Exploration) high-dose cohortA vizsgált kezelés

    Each participant will receive selected high-dose. Once approximately 8 evaluable subjects per arm have completed approximately six weeks of treatment, an initial review of safety and efficacy will be conducted by the SMC to determine if there is one or more sub-optimal dose(s) that should be closed to further recruitment or if dose / regimens require adjustment.

    Kezelés: CID-103

  • Part B (Randomized Dose Exploration) intermediate-dose cohortA vizsgált kezelés

    Each participant will receive selected intermediate-dose. Once approximately 8 evaluable subjects per arm have completed approximately six weeks of treatment, an initial review of safety and efficacy will be conducted by the SMC to determine if there is one or more sub-optimal dose(s) that should be closed to further recruitment or if dose / regimens require adjustment.

    Kezelés: CID-103

  • Part B (Randomized Dose Exploration) low-dose cohortA vizsgált kezelés

    Each participant will receive selected low-dose. Once approximately 8 evaluable subjects per arm have completed approximately six weeks of treatment, an initial review of safety and efficacy will be conducted by the SMC to determine if there is one or more sub-optimal dose(s) that should be closed to further recruitment or if dose / regimens require adjustment.

    Kezelés: CID-103

  • Part A (Dose Escalation) Cohort 1- 30 mg/30 mgA vizsgált kezelés

    This is the initial dose cohort with accelerated dose escalation design. If a Grade ≥ 2 AE is reported in the cohort, the cohort will expand to three subjects and the study will then convert to a standard 3+3 design.

    Kezelés: CID-103

  • Part A (Dose Escalation) Cohort 1- 30 mg/150 mgA vizsgált kezelés

    This is the second dose cohort with accelerated dose escalation design. If a Grade ≥ 2 AE is reported in the cohort, the cohort will expand to three subjects and the study will then convert to a standard 3+3 design.

    Kezelés: CID-103

  • Part A (Dose Escalation) Cohort 1- 150 mg/300 mgA vizsgált kezelés

    This is the third dose cohort with accelerated dose escalation design. If a Grade ≥ 2 AE is reported in the cohort, the cohort will expand to three subjects and the study will then convert to a standard 3+3 design.

    Kezelés: CID-103

  • Part A (Dose Escalation) Cohort 1- 150 mg/600 mgA vizsgált kezelés

    This is the fourth dose cohort with standard 3+3 design.

    Kezelés: CID-103

  • Part A (Dose Escalation) Cohort 1- 150 mg/900 mgA vizsgált kezelés

    This is the fifth dose cohort with standard 3+3 design.

    Kezelés: CID-103

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07017725: ki vehet részt
A regiszteradat frissítve
2025. június 12.